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Infections in Adult Liver Transplant Patients Under 
FK 506 Immunosuppression 
M. Alessiani. S. Kusne. M. Martin. A. Jain. K. Abu-Elmagd. J. Moser. S. Todo. J. Fung. and T. Starzl 
THE preliminary results of infectious complications in 
orthotopic liver transplantation IOLT) using FK 506 
as a primary immunosuppressive agent were encouraging. I 
This early experience. however. was limited to only 20 
patients who were followed for a short period of time. We 
have now extended our observations to 110 consecutive 
adult liver transplant recipients of first livers enrolled in the 
first human clinical trial of OL T under FK 506. A longer 
follow-up period 15 to 12 months) has allowed us to 
compare FK 506 with previous studies of infections in the 
cyclosporine ICy Al era; and to assess whether this new 
agent alters the infectious profile and overall rate of 
infection. The influence of FK 506 on well established risk 
factors for infection were specifically addressed. and in· 
c1ude preoperative patient status. requirement for addi-
tional immunosuppression. reoperation. and retransplan-
tation. 
METHODS 
The patient population included 110 consecutive adults who 
underwent OLT between August 18. 1989 and february 18. 1990. 
All patients were followed prospectively from the time of surgery 
to discharge or death. Out-patient follow-up continued until July 
1. 1990. General characteristics and indications for OL T arc 
summarized in Table I. The mean age was 40 :!: 12 years. with 17 
patients older than 60 years of age. There were 58 males and 52 
females. Mean follow-up was 214 :!: 50 davs with a range of 134 to 
315 days. Eight-five patients were senously ill (status 3. 4. or 
UNOstatl. as defined by the current United Network for Organ 
Sharing IUNOS) stratification: status I. at home. functioning 
Without domiciliary nursing care: status 2. at home. not working 
and reqUiring profeSSional nursing care: status 3. hospital bound: 
status 4. intensive care unit bound. UNOstat-ICU bound requiring 
life support. The most frequent indication for OL T was nonalco-
holic cirrhosis followed by alcoholic and cholestatic liver disease. 
Immunosuppression 
Immunosuppression protocol included fK 506 and steroids in all 
patients. The first 57 patients received fK 506 as an IV loading 
dose of 0.15 mglkg followed by an IV maintenance dose of 0.075 
mglkg twice a day. Conversion from IV to oral doses was usually 
overlapped for I day with oral maintenance doses of 0.15 mglkg 
given every 12 hours. Initial steroid therapy included a I g I V 
bolus of methylprednisolone intraoperatively. A 200 mg dose on 
the first postoperative day was then reduced by 40 mg increment~ 
10 a maintenance dose of 20 mg by day 6. The subsequent 53 
patients received IV maintenance doses of fK 506 and methyl-
prednisolone from the outset. omittmg Ihe loading dose of fK 5()t) 
and both the steroid bolus and taper. Subsequent ad.iustmenh 
were dictated by the quality of the grafL the presence of rejection. 
toxicity symptoms. and the fK 506 plasma levels. 
Table 1. Patient Population and Indications for OL Tx 
Demographics 
No. of patients 110 
No. of transplants 124 
Age (y) 46 + 12 (18 to 69) 
Sex (M/F) 58/52 
Mean follow-up (d) 214 + 50 
Indications 
NonalcoholiC CirrhoSIS 45 (41.0%) 
Alcoholic CirrhoSIS 28 (25.5%) 
Cholestatlc disease 28 (25.5%) 
Fulminant failure 3 (2.7%) 
Tumor 2 (1.8%) 
Miscellaneous 4 (3.5%) 
Infection ProphylaxiS 
The patients received perioperatlve IV cefotaxime and ampicillin 
3 gld which was continued for the first 3 days after tmnsplant. Oral 
mycostatin 2 million U/d was given for the first 6 months. High 
dose oral acyclovir ranging from 400 mg to 3200 mgld was given 
with dose adjustment according to renal function. One tablet of 
Bactrim SS daily (80 mg of trimethoprim plus 400 mg of sulfa-
methoxazolel was given for almost I year. 
Definition of Infections 
We followed the definitions of infections described by Kusne et al~ 
from our institution with classification done according to the time 
of diagnosis. maior pathogen. and site of occurrence. An infection 
was considered to be associated with death if it was found at the 
autopsv or if the patient was still under treatment for the infection 
at the time of death. An infeclion was defined as severe if it 
Involved solid organs or cavities and required treatment with 
specific antibiotics and/or surgical intervention. Examples of 
severe infections in this study included peritonitis. pneumonia. 
cholangitis. abdominal or liver abscess. pericarditis. symptomatic 
CMV and Epstein-Barr virus (EBV) infections. invasive candidi-
asis. and aspergillosis. Examples of non severe infections included 
line infection. superficial wound infection. colitis. sinusitis. otitis. 
mucocutaneous herpes simplex. and candida colonization. 
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Table 2. Percentage of Patients Infected and the Episodes of 
Infection Per Patient 
% Patients Infected EPISOdes of Inf x PI 
All Several All Several 
Bacterial 36 19 0.58 0.24 
Viral 24 23 0.31 0.28 
Fungal 9 6 0.12 0.06 
Total 50 38 1.01 0.58 
Note: Distinction has been made between severe and overall Infections. 
Sixteen percent of patlllnts suffered overlaPPIng InfectIOns (9% bactenal + viral. 
3% bactenal + fungal. 4% baClenal + wal + fungal) while 34% developed only 
OM type (20% bacterial. ,,% viral. 2% fungal) 
Statistics 
The number of infections per patient was compared between 
patient groups nonparametricallv using the Wilcoxon two-sample 
test for location. Although follow-up time varied from patient to 
patient. follow-up lime was not related to the number of infec-
tions. 
RESULTS 
From July I. 1990 (when data compilation closed) to 
August 16. 1990. 102 (92.79c) of the patients are alive. Ten 
patients underwent retransplantation. with six requiring 
one graft and four. two grafts. Six of these patients are 
alive. Five of eight deaths were due to infection (62.59H 
and three to other causes such as heart failure. stroke. and 
multiorgan failure. Of the infection related deaths. two 
occurred following retransplantation. The majority of bac-
terial and fungal infections were seen within the first 60 
days with viral infections persisting through the first 6 
months. The severity and frequency of infections are 
shown in Table 2. Overall. 50% of patients developed 
infection of which 38% suffered severe ones. Bacterial 
infections predominated with some patients infected with 
mUltiple organisms. Sixty-four episodes of bacterial infec-
tion. which ranged in severity. were noted. A combination 
of viral. bacterial. or fungal infection was noted in 16% of 
the patients while a single type of infection occurred in 
34%. No protozoal infections were seen. Eight of the III 
(7.2%) episodes resulted in death and were predominantly 
bacterial and fungal (7). 
In the bacterial group (Table 3) the most frequent severe 
infections were pneumonia (8). peritonitis (8). and cholan-
gitis (6). The majority of the microorganisms isolated were 
aerobic gram positive (38) and gram negative aerobes (23). 
Anaerobes were unusual with Clostridium difJicile ac-
counting for seven of eight cases. 
Cervical lymphadenitis caused by Mvcohocterium 111-
berculosis was seen in one patient and required prolonged 
treatment with conventional triple therapy (isoniazid. 
ethambutol. and rifampin). However. 3 months later iso-
niazid hepatotoxicity necessitated discontinuation of this 
drug. 
Symptomatic CMY was the most frequent viral infection 
and occurred in 23 patients. The liver and gastrointestinal 
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Table 3. Number of Episodes of Infection That Occurred In 
55 of 110 Patients 
Bacterial (64 r 
Soft tissue 
line sepsIs 
Pneumoma 
Peri/ani/is 
Colitis 
Cholangi/is 
Urinary tract 
SinUSitiS 
Intrabdommal abscess 
Liver abscess 
Pericarditis 
Cervical TB 
Otitis media 
Viral (34) 
CMV 
Herpes Simplex 
EBV 
Fungal (13) 
Candidiaslasis 
Colonized candida 
Aspergillosis 
Note. Severe Inlectlons are Italicized 
'19 episodes of bacteremia are Included. all 01 known ongln. 
(12) 
(11 ) 
(8) 
(8) 
(7) 
(6) 
(5) 
(2) 
(1 ) 
(1 ) 
(1 ) 
(1 ) 
(1 ) 
(27) 
(4) 
(3) 
(5) 
(6) 
(2) 
tract were the predominant sites of infection (eight epi-
sodes each) followed by the lungs (five examples). Three 
patients developed multiple and recurrent episodes of 
CMY at different sites and all were fund to have concom-
itant retinitis as a late manifestation. The first patient was 
a 19-year-old man. retransplanted after 40 days for rejec-
tion. He was seronegative for CMY and received his 
second liver from a seropositive donor. He had a positive 
cytotoxic crossmatch with both donors and heavy immu-
nosuppression was required throughout his early course 
for persistent rejection. Multiple episodes of symptomatic 
CMY subsequently developed and included pneumonia. 
hepatitis. and retinitis at 3. 4. and 6 months respectively. 
Two patients had a similar course with initial episodes of 
CMY infection occurring during the third month posttrans-
plant (hepatitis-I. pneumonia-I) with readmission required 
at 5 months for concomitant CM Y gastritis and retinitis. In 
all cases treatment with DHPG was successful and none of 
the patients had residual sequelae from the retinitis. 
EBY infection associated with polyclonallymphoprolif-
erative disease was confirmed histologically in three pa-
tients. A 19-year-old man developed an infectious mono-
nucleosis syndrome with enlargement of the tonsils and 
was successfully treated with tracheostomy. tonsillec-
tomy. acyclovir. and reduction of the FK dose. The other 
two patients developed polyclonallymphoma arising in the 
allograft. One highly sensitized patient (positive cross-
match with all donors) died of overwhelming pseudomonas 
and candida sepsis 9 days after undergoing a third trans-
plant for rejection. while the other patient whose jym-
phoma was confined to the graft recovered following left 
hepatic segmentectomy. 
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RETRANSPLANTATION REOPERATION 
Fig 1. Effect of additional Immunosuppression (boluses or recy· 
cles of steroids and OKT3) and UNOS status on the Incidence of 
infections. 
Of the five cases of invasive candidiasis. two were 
associated with death. A fatal aspergillosis was seen in a 
31-year-old woman. Twenty-one days after transplant. she 
was noted to have several pulmonary nodules. which 
contained aspergillus on biopsy. She received a full course 
of amphotericin B therapy (3 g total dose). with partial 
regression of these nodules. She then required retransplan-
tatlOn for hepatic artery thrombosis at 3.5 months and 
succumbed to bacterial sepsis and recurrent aspergillus in 
her thoracic spine at 5 months (vertebral osteomyelitis). 
Significant higher rates of infection were seen in the 
sickest pretransplant patients and in those receiving addi-
tIOnal mtense immunosuppression (steroid boluses. recy-
cles. or OKT3) (Fig Il. The need for retransplantation or 
additional surgery was associated with especially high 
rates of infection (Fig 2l. 
DISCUSSION 
Advances in preservation. combined with technical im-
provements. and the routine use of veno-veno bypass have 
contributed to lowering morbidity of OLT. However. the 
intense immunosuppression required under conventional 
therapy continues to play a key role in contributing to 
infectious outcome. 3 .4 
This large series of OL T patients receiving FK 506 has 
confirmed our early enthusiasm for this agent. As reported 
hy Todo et al.s rejection. early graft dysfunction. and the 
need for retransplantation have been reduced in FK 506 
treated patients. The potent immunosuppressive proper-
ties of this drug have allowed for significant reductions in 
steroid use without increasing the risk of rejection. In fact. 
fewer infections were seen. 
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Fig 2. Effect of retransplantation and additional immunosuppres-
sion on incidence of Infections. The differences are statistically 
significant (P < .05). 
The patterns and timing of the infections that did occur 
were similar to those developing under conventional ther-
apy. with bacterial and fungal infections predominating 
early in the course. However. 50% of patients receiving 
FK 506 were entirely free of infections compared with only 
179t in the historical controls from Kusne's earlier report 
from our institution. ~ Although infection continues to 
cause or be associated with the majority of deaths. the 
death rate has been reduced. 
Symptomatic CMV remains the most common infec-
tion. However. all herpes infections have been signifi-
cantly less. an improvement that may be related to recent 
changes in prophylaxis with the use of acyclovir. The 
notable absence of protozoal infections can be explained. 
at least in parI. in the same way. 
High risk factors continue to be retransplantation. reop-
eration. intense additional immunosuppression in the man-
agement of rejection. and grave deterioration from end-
stage liver disease going into transplantation. However. 
the poor prognostic portent of these risk factors has 
seemed less grim in the FK 506 treated patients than in the 
past. A generally good quality of liver graft function. which 
has been achievable with low (and often no) dose steroids 
appears to be the explanation for the improved outlook. 
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